MCID: DMY001
MIFTS: 43

Demyelinating Polyneuropathy malady

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Demyelinating Polyneuropathy

Aliases & Descriptions for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 14
Peripheral Demyelinating Neuropathy 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 47 C27062
SNOMED-CT 64 23414001
UMLS 69 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to chronic myelomonocytic leukemia and chronic inflammatory demyelinating polyneuropathy. An important gene associated with Demyelinating Polyneuropathy is MAG (Myelin Associated Glycoprotein), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs alemtuzumab and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and endothelial, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
id Related Disease Score Top Affiliating Genes
1 chronic myelomonocytic leukemia 29.6 AIF1 CNTN2 HP TTR
2 chronic inflammatory demyelinating polyneuropathy 12.5
3 subacute inflammatory demyelinating polyneuropathy 12.1
4 pcwh syndrome 11.9
5 neuropathy, inflammatory demyelinating 11.7
6 guillain-barre syndrome 11.4
7 polyneuropathy 11.0
8 charcot-marie-tooth disease, type 2e 11.0
9 canomad syndrome 10.9
10 charcot-marie-tooth disease, type 1b 10.9
11 charcot-marie-tooth disease, type 1e 10.9
12 charcot-marie-tooth disease, x-linked recessive, 5 10.9
13 neuropathy 10.4
14 denture stomatitis 10.2 PMP22 TTR
15 tibial nerve palsy 10.2 PMP22 TTR
16 acute female pelvic peritonitis 10.2 APOA4 TTR
17 myelodysplastic myeloproliferative cancer 10.2 CNTN2 FCGR2B
18 fruit allergy 10.2 CNTN1 NFASC
19 cd3zeta deficiency 10.2 CNTN1 NFASC
20 hematocele of tunica vaginalis testis 10.2 HP TTR
21 potocki-lupski syndrome 10.2 MAG PMP22
22 phaeochromocytoma 10.2 ALB TTR
23 pancreatic vasoactive intestinal peptide producing tumor 10.2 PMP22 TTR
24 ehlers-danlos syndrome, periodontal type 1 10.2 ALB TTR
25 male genital organ stricture 10.1 ALB TTR
26 hepatitis 10.1
27 female infertility of uterine origin 10.1 ALB TTR
28 hypotrichosis 6 10.1 PMP22 TTR
29 inner ear disease 10.1 ALB TTR
30 cataract 10.1 ALB TTR
31 congenital nonspherocytic hemolytic anemia 10.1 ALB TTR
32 meningeal melanoma 10.1 AIF1 TTR
33 erythema infectiosum 10.1 ALB TTR
34 peripheral vascular disease 10.1 ALB TTR
35 glomangiosarcoma 10.1 FCGR2B MAG PMP22
36 poems syndrome 10.1
37 von economo's disease 10.1 ALB PMP22
38 hypermobility of coccyx 10.0 NGF PMP22
39 spastic entropion 10.0 ALB HP TTR
40 focal epithelial hyperplasia 10.0 ALB HP TTR
41 myasthenia gravis 10.0
42 melanoma 10.0
43 choreatic disease 10.0 ALB HP PMP22
44 charcot-marie-tooth disease 10.0
45 hepatitis b 10.0
46 multifocal motor neuropathy 10.0
47 lymphoma 10.0
48 tooth disease 10.0
49 systemic lupus erythematosus 9.9
50 hepatitis c 9.9

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 APOA4 CNTN1 CNTN2 FCGR2B MAG NFASC
2 homeostasis/metabolism MP:0005376 9.85 AIF1 ALB APOA4 FCGR2B HP MAG
3 mortality/aging MP:0010768 9.61 FCGR2B HP NFASC NGF PMP22 PTGDS
4 nervous system MP:0003631 9.32 FCGR2B MAG NFASC NGF PMP22 PTGDS

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
2 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
3 gamma-Globulins Phase 4,Phase 3,Phase 2
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
5 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
6 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
9
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
10
Mycophenolic acid Approved Phase 3 24280-93-1 446541
11
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
12
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
13 tannic acid Approved, Nutraceutical Phase 3
14 Anti-Inflammatory Agents Phase 3
15 Antineoplastic Agents, Hormonal Phase 3
16 glucocorticoids Phase 3
17 Hormone Antagonists Phase 3,Phase 2
18 Hormones Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
20 Immunoglobulin G Phase 3
21 3,4-diaminopyridine Phase 3
22 Potassium Channel Blockers Phase 3,Phase 2
23 Antirheumatic Agents Phase 3,Phase 2
24 Fingolimod Hydrochloride Phase 3
25 Immunosuppressive Agents Phase 3,Phase 2
26 Bile Acids and Salts Phase 3
27 Cholic Acids Phase 3
28 Gastrointestinal Agents Phase 3
29 Liver Extracts Phase 3
30 Pharmaceutical Solutions Phase 3,Phase 2
31 Anti-Bacterial Agents Phase 3
32 Antibiotics, Antitubercular Phase 3
33
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
34
4-Aminopyridine Approved Phase 2 504-24-5 1727
35
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
36
Busulfan Approved, Investigational Phase 2 55-98-1 2478
37
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
38
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
39
Thiotepa Approved Phase 2 52-24-4 5453
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
41
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
42 Complement System Proteins Phase 2
43 Antioxidants Phase 2
44 Micronutrients Phase 2
45 Protective Agents Phase 2
46 Thioctic Acid Phase 2
47 Trace Elements Phase 2
48 Vitamin B Complex Phase 2
49 Vitamins Phase 2
50 Antibodies, Monoclonal Phase 2

Interventional clinical trials:

(show top 50) (show all 73)
id Name Status NCT ID Phase
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4
2 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4
3 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3
4 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
5 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3
6 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
7 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3
9 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3
10 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3
11 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3
12 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3
13 Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Completed NCT00007020 Phase 3
14 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3
15 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3
16 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
17 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
18 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Recruiting NCT02293460 Phase 3
19 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Recruiting NCT02317562 Phase 3
20 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Active, not recruiting NCT02027701 Phase 3
21 Interest of Mycophenolate for CIDP Weaning Active, not recruiting NCT02494505 Phase 3
22 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3
23 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Not yet recruiting NCT02638207 Phase 3
24 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3
25 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2
26 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2
27 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2
28 Rituximab to Treat Neuropathy With Anti-MAG Antibodies Completed NCT00050245 Phase 2
29 JET-GBS - Japanese Eculizumab Trial for GBS Completed NCT02493725 Phase 2
30 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2
31 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2
32 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2
33 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
34 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2
35 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2
36 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Recruiting NCT02780570 Phase 2
37 MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis Recruiting NCT02171104 Phase 2
38 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
39 Thrombolysis in Ischemic Spinal Cord Stroke Active, not recruiting NCT02242084 Phase 2
40 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2
41 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2
42 Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
43 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
44 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
45 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
46 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
47 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
48 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590
49 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
50 Study of CIDP Patients During IVIG Treatment Completed NCT00305266

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

39
T Cells, B Cells, Endothelial, Skin, Brain, Spinal Cord, Tongue

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 659)
id Title Authors Year
1
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
2
Gastroduodenal Burkitt Lymphoma Presenting as Demyelinating Polyneuropathy. ( 28532696 )
2017
3
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
4
Demyelinating polyneuropathy in a case of anti-LGI1 encephalitis. ( 28073143 )
2017
5
Poster 200 Demyelinating Polyneuropathy Post-Operatively in a Patient with Squamous Cell Carcinoma of the Tongue: A Case Report. ( 27672963 )
2016
6
Postural tremor and chronic inflammatory demyelinating polyneuropathy. ( 27421831 )
2016
7
Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. ( 26843559 )
2016
8
Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. ( 27401495 )
2016
9
Systemic Lupus Erythematosus With Acute Inflammatory Demyelinating Polyneuropathy: A Case Report and Review of the Literature. ( 27298667 )
2016
10
Knowing what's right: Which analgesic is recommended for a patient suffering from demyelinating polyneuropathy and scheduled for rotator-cuff repair? ( 27338205 )
2016
11
Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy. ( 26900579 )
2016
12
Erythromelalgia-like presentation of chronic acquired demyelinating polyneuropathy in a setting of past alcohol abuse. ( 26804376 )
2016
13
Challenges in pediatric chronic inflammatory demyelinating polyneuropathy. ( 27793469 )
2016
14
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. ( 27930572 )
2016
15
Poster 487 Chronic Inflammatory Demyelinating Polyneuropathy or Something Else?: A Case Report. ( 27673228 )
2016
16
The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. ( 27389526 )
2016
17
Evaluation of Patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy. ( 27463215 )
2016
18
Intrathecal Dexmedetomidine for Anaesthetic Management of a Patient with Chronic Inflammatory Demyelinating Polyneuropathy. ( 27790558 )
2016
19
Anti-ganglioside antibodies in Guillain-BarrAc syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. ( 27464289 )
2016
20
Chronic inflammatory demyelinating polyneuropathy variant (Lewis- Sumner syndrome) in HIV. ( 27727849 )
2016
21
Poster 373-A Immunoglobulin Treatment of Miller Fisher Variant of Acute Demyelinating Inflammatory Polyneuropathy with Underlying Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 27673265 )
2016
22
NADPH oxidase 2 (NOX2) enzyme activation in patients with chronic inflammatory demyelinating polyneuropathy. ( 26924156 )
2016
23
Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. ( 27986399 )
2016
24
Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP). ( 27677703 )
2016
25
Novel Therapeutic Avenues for Chronic Inflammatory Demyelinating Polyneuropathy: The Difficulties of Disease Diversity. ( 27211536 )
2016
26
Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation. ( 26919852 )
2016
27
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. ( 27455854 )
2016
28
Poster 304 Protracted Course of Inpatient Rehabilitation in a Patient with Severe Acute Demyelinating Polyneuropathy. ( 27673061 )
2016
29
Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy. ( 26809024 )
2016
30
Chronic inflammatory demyelinating polyneuropathy associated with Rickettsia conorii: First case report. ( 27871450 )
2016
31
Early Electrodiagnostic Features of Upper Extremity Sensory Nerves Can Differentiate Axonal Guillain-BarrAc Syndrome from Acute Inflammatory Demyelinating Polyneuropathy. ( 27819421 )
2016
32
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report. ( 27673107 )
2016
33
Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy. ( 26968516 )
2016
34
The electrophysiological response to immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. ( 27546708 )
2016
35
A case of intravenous immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy of pure motor form responsive to mycophenolate mofetil therapy. ( 27680225 )
2016
36
Incidence and Natural History of Idiopathic Chronic Inflammatory Demyelinating Polyneuropathy: A Population-Based Study in Iceland. ( 27211228 )
2016
37
Diffusion tensor imaging can be used to detect lesions in peripheral nerves in patients with chronic inflammatory demyelinating polyneuropathy treated with subcutaneous immunoglobulin. ( 27114080 )
2016
38
Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-I+ Therapy With Infliximab for Crohn's Disease. ( 27144200 )
2016
39
Poster 224 Giant Cell Myocarditis Masked by Acute Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 27672982 )
2016
40
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). ( 27208993 )
2016
41
Electrophysiological and neuromuscular stability of persons with chronic inflammatory demyelinating polyneuropathy (CIDP). ( 27997686 )
2016
42
Chronic inflammatory demyelinating polyneuropathy associated with manic symptoms. ( 27571998 )
2016
43
Disease activity in chronic inflammatory demyelinating polyneuropathy. ( 27653889 )
2016
44
The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. ( 27086491 )
2016
45
Poster 11 A Rare Case of Chronic Inflammatory Demyelinating Polyneuropathy in the Setting of SLE: A Case Report. ( 27672778 )
2016
46
Sialylated IgG-Fc: a novel biomarker of chronic inflammatory demyelinating polyneuropathy. ( 25814494 )
2015
47
Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. ( 25976871 )
2015
48
Conducting processes in simulated chronic inflammatory demyelinating polyneuropathy at 20A^C-42A^C. ( 25597276 )
2015
49
Increase of distal sensory action potential duration as a sensitive electrophysiological parameter in atypical case of acute inflammatory demyelinating polyneuropathy. ( 26573592 )
2015
50
Dramatic Improvement of Chronic Inflammatory Demyelinating Polyneuropathy Through Tenofovir Treatment in a Patient Infected with Hepatitis B Virus. ( 25850895 )
2015

Variations for Demyelinating Polyneuropathy

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.77 CNTN2 MAG NFASC NGF
2
Show member pathways
11.43 CNTN1 CNTN2 NFASC
3 11.09 CNTN1 CNTN2 MAG NFASC

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.5 ALB APOA4 HP
2 node of Ranvier GO:0033268 9.26 CNTN2 NFASC
3 paranode region of axon GO:0033270 9.16 MAG NFASC
4 myelin sheath GO:0043209 9.02 ALB CNTN1 CNTN2 MAG NFASC
5 compact myelin GO:0043218 8.96 MAG PMP22

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.5 ALB APOA4 TTR
2 peripheral nervous system development GO:0007422 9.26 NFASC PMP22
3 high-density lipoprotein particle remodeling GO:0034375 9.16 ALB APOA4
4 central nervous system myelination GO:0022010 8.96 CNTN2 MAG
5 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.33 CNTN1 CNTN2 MAG
2 fatty acid binding GO:0005504 8.96 ALB PTGDS
3 antioxidant activity GO:0016209 8.8 ALB APOA4 HP

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....